首頁 > 市場調查報告書 > 製藥

分子標靶治療學

市場調查報告書

商品編碼

1906301

全球 CD137 標靶治療市場：市場機會、治療方法、技術開發平台與臨床試驗展望（2026 年）

Global CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026

出版日期: 2026年01月01日 | 出版商:

KuicK Research | 英文 270 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球 CD137 標靶治療市場 - 市場機會、治療方法、技術開發平台和臨床試驗展望（2026 年）要點：

預計首支 CD137 標靶療法將於 2030 年前上市。
CD137 標靶療法臨床試驗概況：超過 90 種療法
CD137 標靶療法臨床試驗概況（按公司、國家/地區、適應症和階段劃分）
大多數臨床試驗：III 期
各公司 CD137 標靶療法的專有技術平台
全球和區域趨勢（臨床和商業）
CD137 標靶治療方法

對 CD137 標靶療法的需求CD137標靶療法及其在本報告中的意義

CD137 (4-1BB) 是一種重要的共刺激受體，對 T 細胞的活化、存活和增殖至關重要。它也被認為在增強抗腫瘤免疫反應中發揮關鍵作用，使其成為癌症免疫療法中最有價值的目標之一。儘管免疫腫瘤學近年來取得了進展，但目前的治療方法，例如化療和免疫檢查點抑制劑，在療效方面仍面臨許多挑戰，尤其是在實體瘤患者中。 CD137標靶療法有望透過直接刺激腫瘤微環境中的免疫細胞並增強身體的抗癌能力來應對這些挑戰。

本報告旨在探討人們對CD137標靶療法日益增長的興趣，詳細介紹正在進行的臨床試驗，介紹新興技術，並介紹推動創新的公司。本報告從描述臨床開發各個階段的進展，到概述影響各種 CD137 標靶治療策略未來發展的競爭格局和科學前景，重點闡述了 CD137 調控在腫瘤治療中的潛力。

本報告涵蓋的臨床研究和試驗概覽

本報告全面深入地介紹了正在進行的 CD137 標靶治療臨床研究和試驗，使利害關係人能夠清晰了解該領域的治療進展。報告分析了從早期試驗到更高級研究的各個臨床階段。這些試驗涉及多種適應症，尤其關注實體腫瘤和血液系統惡性腫瘤。報告還討論了正在進行的聯合治療試驗，重點闡述了 CD137 標靶藥物如何與化療和其他免疫療法（包括 PD-1 抑制劑和 VEGF 抑制劑）聯合使用，以提高整體療效。本綜述也總結了新興的臨床數據，並評估了標靶 CD137 療法的安全性和有效性，為推進這些療法的發展提供了重要見解。

本報告涵蓋的技術平台

本報告進一步概述了推動標靶 CD137 療法研發創新的技術平台。例如，AP Biosciences 的 T-cube 平台能夠產生雙特異性抗體，這些抗體僅在與腫瘤特異性抗原結合時才能透過 CD137 選擇性地活化 T 細胞。這種特異性有望最大限度地減少脫靶毒性，例如其他免疫療法中常見的細胞激素風暴。這些技術平台為更具標靶性、更安全、潛在更有效的治療提供了環境，代表了癌症免疫療法的突破。本報告概述了這些平台，並評估了它們對未來標靶 CD137 療法的影響。

參與 CD137 標靶療法研發的關鍵公司

老牌製藥巨頭和新興生技公司都在 CD137 標靶療法的研發中發揮主導作用。羅氏、Genmab 和四川百利藥業等領先公司正積極推動 CD137 標靶療法的臨床試驗。 ABL Bio 和 Pieris Pharmaceuticals 等中小型公司也透過探索新型雙特異性抗體和遞送系統，不斷豐富研究領域。本報告深入分析了這些關鍵公司、其研發管線和策略，以及 CD137 標靶療法的進展，清楚展現了這一快速發展領域的競爭格局。

報告：CD137 標靶療法的未來發展方向

本報告對 CD137 標靶療法的未來發展方向進行了全面且前瞻性的分析。該領域正不斷發展，新的創新有望克服現有挑戰，例如免疫抗藥性和細胞激素釋放症候群等副作用。此外，將CD137激動劑與其他免疫檢查點抑制劑或標靶療法合併應用的聯合療法，具有克服單藥療法限制的巨大潛力。鑑於正在進行的臨床試驗和不斷湧現的數據，CD137標靶療法有望在癌症治療中發揮日益重要的作用。本報告深入分析了這些新興趨勢，使利害關係人能夠預測這一前景廣闊的領域未來的發展方向及其對腫瘤學領域的潛在影響。

ABL Bio
Adagene
Alligator Bioscience
BeOne Medicines
Bicycle Therapeutics
BioNTech
Crescendo Biologics
Compass Therapeutics
Eutilex
F-star Therapeutics
Genmab
NovaBridge Biosciences
Kyinno Biotechnology
Lyvgen Biopharma
Obsidian Therapeutics
OriCell Therapeutics
Palvella Therapeutics
上海亨利生物科技
四川百利藥業
SystImmune

簡介目錄圖表

Global CD137 Targeted Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026 Report Highlights:

First CD137 Targeted Therapy Commercial Launch Expected By 2030
Insight On CD137 Targeted Therapies In Clinical Trials: > 90 Therapies
CD137 Targeted Therapies Clinical Trials Insight By Company, Country, Indication and Phase
Highest Clinical Trials Phase: Phase III
CD137 Targeted Therapies Proprietary Technology Platforms By Companies
Global & Regional Trends (Clinical & Commercial)
Therapeutic Approaches For Targeting CD137

CD137 Targeted Therapies Need & Why This Report?

CD137 or 4-1BB, is a co-stimulatory receptor important for T-cell activation, survival, and expansion. It is also recognized for playing a critical role in augmenting anti-tumor immune responses, hence becoming one of the most valued targets in cancer immunotherapy. Notwithstanding recent progress made in immune oncology, current treatments such as chemotherapy and immune checkpoint inhibitors have some shortcomings regarding their efficacy among patients, especially those with solid tumors. CD137 targeting therapies can bridge these gaps through the direct stimulation of immune cells in the tumor microenvironment, leveraging the body to better combat cancer.

The report covers the increasing enthusiasm for CD137-targeted therapies, underlining the details of ongoing clinical trials, emerging technologies, and identifying companies that are driving the innovation process. It underlines the therapeutic potential of CD137 modulation in oncology: from describing progress made at different stages of clinical development to outlining the competitive and scientific landscape forming the future for various CD137-targeted treatment strategies.

Clinical Studies & Trials Insight Included In Report

The report provides comprehensive insights into the ongoing clinical studies and trials for CD137 targeted therapies, enabling stakeholders to take a clear view of the therapeutic progress of this field. An analysis is provided of various clinical stages that range from early-phase trials to more advanced studies. These trials involve research into a range of indications, with particular attention to solid tumors and hematological malignancies. Ongoing combination therapy trials are also discussed, concerned with the investigation into how agents targeting CD137 may act in concert with chemotherapies or other immunotherapies-including PD-1 or VEGF inhibitors-to improve overall efficacy. This review also identifies the emerging clinical data and assesses the safety and efficacy profiles of CD137-targeted therapies, providing critical insight into the way forward for these therapies.

Technology Platforms Included In Report

The report further profiles technology platforms driving innovations in CD137 targeted therapy development. Examples include AP Biosciences' T-cube, a platform enabling the creation of bispecific antibodies that selectively activate T-cells through CD137 only upon binding to tumor-specific antigens. This specificity offers the promise of minimal off-target toxicities, such as cytokine storms, common with other immune therapies. These technology platforms represent a quantum leap in cancer immunotherapy by providing an enabling environment for more targeted, safer, and probably more effective therapies. The report provides an overview of such platforms and assesses their implications for future CD137 targeted therapies.

Leading Companies Involved In R&D of CD137 Targeted Therapies

Established pharmaceutical giants and emerging biotech companies both lead in the development of CD137 targeted therapies. Major players such as Roche, Genmab, and Sichuan Baili Pharmaceutical are actively advancing their CD137-targeting therapies in clinical trials. Smaller firms like ABL Bio and Pieris Pharmaceuticals continue to bring in diversity into the research landscape by exploring novel bispecific antibodies and delivery systems. This report describes those key companies, insights into their pipelines and strategies, and the progress of their CD137 targeted therapies in order to give a clear picture of the competitive landscape in this rapidly evolving field.

Report Indicating Future Direction of CD137 Targeted Therapies

Looking ahead, the report comprehensively analyzes the future direction of CD137 targeted therapies. The landscape is continuously evolving, with new innovations likely to overcome some of the existing challenges related to immune resistance and side effects such as cytokine release syndrome. Furthermore, combination therapies that combine CD137 agonists with other immune checkpoint inhibitors or targeted treatments offer significant potential for overcoming limitations observed in monotherapies. In the context of ongoing clinical trials and the emergence of new data, the role of CD137 targeted therapies is likely to be increasingly important in cancer treatment. This report provides key insights into these emerging trends, enabling stakeholders to anticipate the future direction of this promising field and its likely impact on the oncology landscape.

1. Research Methodology

2. Brief Introduction To CD137

2.1 Clinical Overview
2.2 Biological History Of CD137
2.3 CD137 Hosting An Era Of Agonists Over Antagonists
2.4 Bi-Directional Signaling In CD137

3. Global CD137 Targeted Therapy Market Outlook

3.1 Current Research & Market Scenario
3.2 Future Commercialization Opportunities

4. CD137 Targeted Therapy Clinical Innovation Trends By Region

4.1 China
4.2 South Korea
4.3 US
4.4 Europe
4.5 Australia

5. CD137 Role & Clinical Progress By Indication

5.1 Cancer
- 5.1.1 Leukemia
- 5.1.2 Lymphoma
- 5.1.3 Lung Cancer
- 5.1.4 Melanoma
- 5.1.5 Breast Cancer
- 5.1.6 Colorectal Cancer
5.2 Autoimmune & Inflammatory Diseases
5.3 Microbial Infections
5.4 Neuronal Diseases

6. Global CD137 Targeted Therapies Clinical Trials Overview

6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Phase

7. CD137 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase

7.1 Research
7.2 Preclinical
7.3 Phase I
7.4 Phase I/II
7.5 Phase II
7.6 Phase III

8. CD137 Targeted Therapy Proprietary Technology Platforms By Companies

9. Therapeutic Approaches For Targeting CD137

9.1 Antibodies
- 9.1.1 Monoclonal antibodies
- 9.1.2 Bispecific Antibody Centered Approaches
- 9.1.3 Trispecific Antibody Established Strategies
- 9.1.4 Tetraspecific Antibody Strategies
- 9.1.5 Single-chain variable fragments
9.2 Peptides
9.3 Protein-Based Therapeutics

10. Combination Therapies With CD137 Targeted Therapy

11. Competitive Landscape

11.1 ABL Bio
11.2 Adagene
11.3 Alligator Bioscience
11.4 BeOne Medicines
11.5 Bicycle Therapeutics
11.6 BioNTech
11.7 Crescendo Biologics
11.8 Compass Therapeutics
11.9 Eutilex
11.10 F-star Therapeutics
11.11 Genmab
11.12 NovaBridge Biosciences
11.13 Kyinno Biotechnology
11.14 Lyvgen Biopharma
11.15 Obsidian Therapeutics
11.16 OriCell Therapeutics
11.17 Palvella Therapeutics
11.18 Shanghai Henlius Biotech
11.19 Sichuan Baili Pharmaceutical
11.20 SystImmune

簡介目錄圖表

List of Figures

Figure 2-1: Evolution Of Cancer Immunotherapy Approaches
Figure 2-2: Biological Effects Triggered By CD137 Stimulation
Figure 2-3: CD137 - Discovery & Early Biological Characterization
Figure 2-4: Mechanistic Pathways Triggered By CD137 Ligation
Figure 2-5: Anti-CD137 Monoclonal Antibody - Immune Regulation Mechanisms
Figure 2-6: Why CD137 Became An Important Target
Figure 2-7: Schematic Depiction Of Bidirectional Signaling By CD137-CD137L
Figure 2-8: CD137 - Forward Signaling Cascade in Immune Cells
Figure 2-9: CD137L - Reverse Signaling
Figure 2-10: Bidirectional Signaling Loop Between CD137 & CD137L
Figure 3-1: Global CD137 Targeting Therapy Market - Future Opportunities
Figure 5-1: Bidirectional CD137-CD137L Signaling in Leukemia Cell Survival
Figure 5-2: GNC-035-105 Phase Ib/II (NCT05944978) Study - Initiation & Completion Year
Figure 5-3: GNC-035-105 Phase I (NCT05944978) Study - Initiation & Completion Year
Figure 5-4: GNC-038-101 Phase I (NCT04606433) Study - Initiation & Completion Year
Figure 5-5: Lymphoma - CD137's Role In Countering Immune Evasion
Figure 5-6: BP41072 Phase I/II (NCT04077723) Study - Initiation & Completion Year
Figure 5-7: YH004003 Phase I (NCT05564806) Study - Initiation & Completion Year
Figure 5-8: IBD0333-101 Phase I/II (NCT06292208) Study - Initiation & Completion Year
Figure 5-9: Lung Cancer - Rationale For Targeting CD137
Figure 5-10: BT7480-100 Phase I/II (NCT05163041) Study - Initiation & Completion Year
Figure 5-11: GCT1046-04 Phase 2 (NCT05117242) Study - Initiation & Completion Year
Figure 5-12: HLX35-FIH101 Phase I (NCT05360381) Study - Initiation & Completion Year
Figure 5-13: EU-CTS101-I-01 Phase I/II (NCT04903873) Study - Initiation & Completion Year
Figure 5-14: Melanoma - CD137 As A Costimulatory Driver Of Disease Immunity 71
Figure 5-15: FS222-19101 Phase I (NCT04740424) Study - Initiation & Completion Year
Figure 5-16: LBL-024-CN007 Phase I/II (NCT07099430) Study - Initiation & Completion Year
Figure 5-17: ABBIL1TY MELANOMA-07 Phase II (NCT06984328) Study - Initiation & Completion Year
Figure 5-18: Breast Cancer - Dual Role Of CD137 In Disease Biology
Figure 5-19: BT7480-100 Phase I/II (NCT05163041) Study - Initiation & Completion Year
Figure 5-20: AP402-101 Phase I/II (NCT06669975) Study - Initiation & Completion Year
Figure 5-21: AVIATOR Phase 2 (NCT03414658) Study - Initiation & Completion Year
Figure 5-22: ADG106-T6002 Phase 1/2 (NCT05275777) Study - Initiation & Completion Year
Figure 5-23: YH32367-101 Phase I/II (NCT05523947) Study - Initiation & Completion Year
Figure 5-24: GNC-035-103 Phase I (NCT05160545) Study - Initiation & Completion Year
Figure 5-25: EU-CTS101-I-01 Phase I/II (NCT04903873) Study - Initiation & Completion Year
Figure 5-26: NCI-2018-01036 Phase 1 (NCT03290937) Study - Initiation & Completion Year
Figure 5-27: 1002-CL-0101 Phase I (NCT05719558) Study - Initiation & Completion Year
Figure 5-28: BNT314-02 Phase I/II (NCT07079631) Study - Initiation & Completion Year
Figure 5-29: CD137 - Dual Role In Immune Regulation
Figure 5-30: Microbial Infections - CD137 Expression & Immune Roles
Figure 5-31: CD137 In Neuroinflammation
Figure 6-1: Global – CD137 Targeted Therapies Clinical Pipeline by Company (Numbers), 2026
Figure 6-2: Global – CD137 Targeted Therapies Clinical Pipeline by Country (Numbers), 2026
Figure 6-3: Global – CD137 Targeted Therapies Clinical Pipeline by Indication (Numbers), 2026
Figure 6-4: Global – CD137 Targeted Therapies Clinical Pipeline by Phase (Numbers), 2026
Figure 8-1: Adagene – Anti CD137 NEObody ACG106
Figure 8-2: Adagene – Anti CD137 POWERbody ADG206
Figure 8-3: Genmab - DUObody Production Process
Figure 8-4: Genmab - DUObody Platform Detail
Figure 8-5: Crescendo Biologics - Humabody Structure
Figure 8-6: CB307 Humabody – Structure
Figure 8-7: Numab Therapeutics - MATCH Format
Figure 8-8: NM21-1480 - Structure
Figure 8-9: Systimmune – GNC-039 Structure
Figure 8-10: Systimmune – GNC-035 Structure
Figure 8-11: Systimmune – GNC-038 Structure
Figure 8-12: Merus – Multiclonics Structure
Figure 8-13: Chugai Pharmabody Research - Dual-Ig® Technology
Figure 8-14: Eutilex - Costim Platform Technology
Figure 8-15: AND-Body - Ampersand Biomedicines
Figure 8-16: X-body Platform - Leads Biolabs
Figure 8-17: T-cube Bispecific Antibody Platform - AP Biosciences
Figure 8-18: Grabody-T - ABL Bio
Figure 8-19: LEAD-452 Trimerbody – Structure
Figure 9-1: ATOR-1017 – Mechanism Of Action
Figure 9-2: EU101 – Mode Of Action
Figure 9-3: LVGN6051 – Mechanism Of Action
Figure 9-4: Ragistomig – Structure & Mechanism Of Action
Figure 9-5: FS120 – Improving PD-1 & Chemotherapy Responses
Figure 9-6: FS222 – Structure
Figure 9-7: FS222 – Mechanism Of Action
Figure 9-8: MP0310 – Mechanism Of Action
Figure 9-9: CD137 Targeting GNC Tetraspecific Antibodies
Figure 9-10: CD137 Targeting Peptide - Mechanism
Figure 9-11: CD137 Targeting Fusion Protein - Conditional Activation Design